Glucocorticoid use and abuse in SLE

Rheumatology (United Kingdom)

Volumn 51, Issue 7, 2012, Pages 1145-1153

  Ruiz Irastorza, Guillermo ^a   Danza, Alvaro ^a,b   Khamashta, Munther ^c  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Anti malarials; Damage; HCQ; Methylprednisolone; Mortality; Osteonecrosis; Osteoporosis; Prednisone; Prognosis; SLE

Indexed keywords

BETAMETHASONE; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; HYDROXYCHLOROQUINE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; RITUXIMAB;

ACNE; ANTIINFLAMMATORY ACTIVITY; AVASCULAR NECROSIS; BLINDNESS; BODY MASS; BONE NECROSIS; CARDIOVASCULAR DISEASE; CAROTID ATHEROSCLEROSIS; CATARACT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL (TOPIC); CYTOSOL; DEPRESSION; DIABETES MELLITUS; DNA BINDING; DOSE RESPONSE; DRUG DNA INTERACTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG USE; EUPHORIA; FRACTURE; FRAGILITY FRACTURE; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLAUCOMA; GLUCOSE BLOOD LEVEL; HAIR DISEASE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOMANIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSULIN RESISTANCE; INTRAOCULAR HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LOW DRUG DOSE; LUNG FIBROSIS; META ANALYSIS (TOPIC); MOOD DISORDER; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); MYOPATHY; OBSERVATIONAL STUDY; OPEN ANGLE GLAUCOMA; ORGAN INJURY; OSTEOPOROSIS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOSIS; PURPURA; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN ATROPHY; SKIN BRUISING; SLEEP DISORDER; STRIA; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTOLIC BLOOD PRESSURE; WOUND HEALING IMPAIRMENT;

CORONARY DISEASE; GLUCOCORTICOIDS; HUMANS; HYPERGLYCEMIA; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; OSTEOPOROSIS; SURVIVAL RATE; WORLD HEALTH;

EID: 84863812325     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker410     Document Type: Review

References (72)

1. Hench PS, Kendall EC, Slocumb CH et al. The effects of the adrenal cortical hormone 17-hydroxy-11-dehydrocorticosterone (compound E) on the acute phase of rheumatic fever; preliminary report. Mayo Clin Proc 1949;24:277-97.
2. Buttgereit F, Saag KG, Cutolo M et al. The molecular basis for the effectiveness, toxicity and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. Scand J Rheumatol 2005;34:14-21.
3. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 2005;353:1711-23.
4. Kleiman A, Tuckermann JP. Glucocorticoid receptor action in beneficial and side effects of steroid therapy: lessons from conditional knockout mice. Mol Cell Endocrinol 2007;275:98-108.
5. Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008;4:525-33.
6. Almawi WY, Melemedjian OK. Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. J Leukoc Biol 2002;71:9-15.
7. Schäcke H, Berger M, Rehwinkel H et al. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 2007;275:109-17.
8. Buttgereit F, Burmester GR, Lipworth BJ. Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet 2005;365:801-3.
9. Stahn C, Löwenberg M, Hommes DW et al. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 2007;275:71-8.
10. Buttgereit F, Straub RH, Wehling M et al. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004;50: 3408-17.
11. Buttgereit F, Scheffold A. Rapid glucocorticoid effects on immune cells. Steroids 2002;67:529-34.
12. Schimmer B, Parker K. Adrenocorticotropic hormone, adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's the Pharmacological Basis of Therapeutics, 11th edn. New York: McGraw Hill Professional, 2007:1587-612.
13. Schmid D, Burmester GR, Tripmacher R et al. Bioenergetics of human peripheral blood mononuclear cell metabolism in quiescent, activated, and glucocorticoid-treated states. Biosci Rep 2000;20: 289-302.
14. Buttgereit F, da Silva JA, Boers M et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002; 61:718-22.
15. Lipworth BJ. Therapeutic implications of non-genomic glucocorticoid activity. Lancet 2000;356:87-9.
16. Saag KG, Koehnke R, Caldwell JR et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994;96: 115-23.
17. Da Silva JA, Jacobs JW, Kirwan JR et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006;65:285-93.
18. De Nijs RN. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options. Minerva Med 2008;99:23-43.
19. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777-87.
20. Zonana-Nacach A, Barr SG, Magder LS et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801-8.
21. Bijlsma JW, van der Goes MC, Hoes JN et al. Low-dose glucocorticoid therapy in rheumatoid arthritis: an obligatory therapy. Ann NY Acad Sci 2010;1193:123-6.
22. Buttgereit F, Burmester GR, Lipworth BJ. Inflammation, glucocorticoids and risk of cardiovascular disease. Nat Clin Pract Rheumatol 2009;5:18-9.
23. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract 2009;15:469-74.
24. Gurwitz JH, Bohn RL, Glynn RJ et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994;154:97-101.
25. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004;141:764-70.
26. Ruyssen-Witrand A, Fautrel B, Saraux A et al. Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2010;78:23-30.
27. Doran MF, Crowson CS, Pond GR et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46: 2294-300.
28. Dixon WG, Kezouh A, Bernatsky S et al. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis 2011;70:956-60.
29. Jones R 3rd, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol 2006;17:163-7.
30. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc 2006;81:1361-7.
31. Drug-induced convulsions. Report from Boston Collaborative Drug Surveillance Program. Lancet 1972;2: 677-9.
32. Chambers SA, Allen E, Rahman A et al. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology 2009;48:673-5.
33. Gladman DD, Urowitz MB, Rahman P et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003;30:1955-59.
34. Thamer M, Hernán MA, Zhang Y et al. Prednisone, lupus activity and permanent organ damage. J Rheumatol 2009; 36:560-4.
35. Cervera R, Khamashta MA, Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine 2003;82: 299-308.
36. Faurschou M, Dreyer L, Kamper A et al. Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res 2010;62:873-80.
37. Esdaile JM, Abrahamowicz M, Grodzicky T et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-7.
38. Bruce IN. " Not only... but also" : factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology 2005;44:1492-502.
39. Toloza SMA, Uribe AG, Mcgwin G et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004;50:3947-57.
40. Manzi S, Selzer F, Sutton-Tyrrell K et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:51-60.
41. Manzi S, Meilahn EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol 1997;145:408-15.
42. Petri M, Perez-Gutthann S, Spence D et al. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992;93:513-9.
43. Petri MA, Lakatta C, Magder L et al. Effect of prednisone and HCQ on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994;96:254-9.
44. Doria A, Shoenfeld Y, Wu R et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62:1071-7.
45. Zhang C, Lu L, Li F et al. Evaluation of risk factors that contribute to high prevalence of premature atherosclerosis in Chinese premenopausal systemic lupus erythematosus patients. J Clin Rheumatol 2009;15:111-6.
46. Haque S, Gordon C, Isenberg D et al. Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. J Rheumatol 2010;37:322-9.
47. Roman MJ, Shanker B, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406.
48. Urowitz MB, Ibañez D, Gladman DD. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol 2007;34:70-5.
49. Karp I, Abrahamowicz M, Fortin PR et al. Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus? Arthritis Rheum 2008;59: 169-75.
50. Schanberg LE, Sandborg C, Barnhart HX et al. Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis Rheum 2009;60:1496-507.
51. Zizic TM, Marcoux C, Hungerford DS et al. Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. Am J Med 1985;79: 596-604.
52. Mok CC, Lau CS, Wong RW. Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol 1998;37:895-900.
53. Oinuma K, Harada Y, Nawata Y et al. Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis 2001;60:1145-8.
54. Sayarlioglu M, Yuzbasioglu N, Inanc M et al. Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus. Rheumatol Int Advance Access published 12 May 2011, doi:10.1007/s00296-010-1597-9.
55. Nagasawa K, Tada Y, Koarada S et al. Very early development of steroid-associated osteonecrosis of femoral head in systemic lupus erythematosus: prospective study by MRI. Lupus 2005;14:385-90.
56. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 2009;11:R109.
57. Sabio JM, Vargas-Hitos JA, Navarrete N et al. Effects of low or medium-dose of prednisone on insulin resistance in patients with systemic lupus erythematosus. Clin Exp Rheumatol 2010;28:483-9.
58. Houssiau FA, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis. The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-31.
59. Illei G, Austin HA III, Crane M et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248-57.
60. Yee C-S, Gordon C, Dostal C et al. EULAR randomized controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophsphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis 2003;63:525-9.
61. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350:971-80.
62. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28.
63. Appel GB, Contreras G, Dooley MA et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-12.
64. Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000;343:1156-62.
65. Ugarte A, Danza A, Villar I et al. Medium dose prednisone for induction therapy of lupus nephritis (abstract). Lupus 2011;4:423.
66. Pepper R, Griffith M, Kirwan C et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 2009;24: 3717-23.
67. Lightstone L. Lupus nephritis: where are we now? Curr Opin Rheumatol 2010;22:252-256.
68. Badsha H, Edwards CJ. Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin Arthritis Rheum 2003;32:370-7.
69. Kong KO, Badsha H, Lian TY et al. Low-dose pulse methylprednisolone is an effective therapy for severe SLE flares. Lupus 2004;13:212-3.
70. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zerón P et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010;69:20-8.
71. Fortin PR, Abrahamowicz M, Ferland D et al. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2008;59: 1796-804.
72. Grossman JM, Gordon R, Ranganath VK et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 2010;62:1515-26.